1.	Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: CASVAC0401, NCT01729663
2.	Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: 103A-301, NCT01546571
3.	Phase I/II Study of Vaccination With Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding For Melan-A, MAGE-3, and Survivin Antigens in Patients With Stage IV Cutaneous Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ERLANGEN-DERMA-ER-DC-06, EU-20317, NCT00074230
4.	Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 19 to 90 Sponsor: Other Protocol IDs: SuMo-Sec-01, PEI 0899/01, IRB 07/03, NCT00108875
5.	The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2 Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: pepDCIL2- HMO-CTIL, NCT00279058
6.	Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 07-0652 / 201103308, NCT00683670
7.	Phase I/II Study of Adjuvant Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides in Patients Who Have Undergone Lymphadenectomy for Stage III Melanomal. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MSCMI-21/01/02, MSCMCC 21/01/02, EU-21006, NCT01082198
8.	Study of a DNA Immunotherapy to Treat Melanoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SCIB1-001, NCT01138410
9.	IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 to 75 Sponsor: NCI, Other Protocol IDs: 009-273, R01CA140602, NCT01189383
10.	Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Luc 10-002, NCT01191034
11.	Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: P009-2010DR1082, NCT01308294
12.	Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 to 60 Sponsor: Other Protocol IDs: 6889, CNPq 577582/2008-9, NCT01584115
13.	Peptide Vaccinations Plus GM-CT-01 in Melanoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LUC 10-001, NCT01723813
14.	Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Phase: Phase II Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: CDR0000369699, DFCI-03123, NCT00085397
15.	Phase II Randomized Study of Vaccine Therapy Comprising Irradiated Autologous Tumor Cells Versus Autologous Dendritic Cells Loaded With Irradiated Autologous Tumor Cells in Combination With Sargramostim (GM-CSF) in Patients With Recurrent or Metastatic Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: Over 16 Sponsor: Other Protocol IDs: HOAG-HCC-06-03, NCT00436930
16.	Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CD-2007-01, NCT00610389
17.	Phase II Randomized Study of a Lymphodepleting Conditioning Regimen Comprising Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation Followed by Anti-MART-1 and Anti-gp100 T-Cell Receptor Gene-Engineered Autologous Peripheral Blood Lymphocytes, High-Dose Aldesleukin, and gp100:154-162 or MART-1:26-35(27L) Peptide Vaccination in Patients With Metastatic Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-09-C-0051, 09-C-0051, NCI-P08428, NCT00814684
18.	Study of Gene Modified Immune Cells in Patients With Advanced Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 10-001212, 08-02-020, NCT00910650
19.	Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0416, NCT00960752
20.	Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PHS IRB 06-55, NCT00961376
21.	High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0113, NCT01266603
22.	Vaccine Therapy With or Without Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02580, 10-324-B, N01CM00071, UCCRC-10-324-B, 8445, NCT01307618
23.	Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16545, NCT01437605
24.	Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120045, 12-C-0045, NCT01495572
25.	Trial of pIL-12 Electroporation Malignant Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11854, NCT01502293